HPLC assay for bupropion and its major metabolites in human plasma
Authors:
- 1 September 2005
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 823 (2) , 115-121
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylationClinical Pharmacology & Therapeutics, 2003
- Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6Pharmacogenetics, 2003
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Functional Characterization of Cytochrome P450 2B6 Allelic VariantsDrug Metabolism and Disposition, 2003
- Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking CessationDrugs, 2002
- BupropionDrugs, 2000
- Chirality and Drugs Used in Psychiatry: Nice to Know or Need to Know?Cellular and Molecular Neurobiology, 1999
- Mismatches Between the Home Environment and Physical Capabilities Among Community‐Living Older PersonsJournal of the American Geriatrics Society, 1999
- Enantiomeric Determination of the Phenylmorpholinol Metabolite of Bupropion in Human Plasma Using Coupled Achiral-Chiral Liquid ChromatographyBiomedical Chromatography, 1997
- Pharmacological significance of the species differences in bupropion metabolismXenobiotica, 1987